Investment, Funding & Disinvestments

The declaration reaffirms commitments by UN Member States to strengthen pandemic preparedness, improve coordination and protect populations from infectious disease threats.

FuturePharma will support the development, scale up and production of pharmaceutical technologies, helping to address a persistent challenge in the industry: translating scientific discoveries into products that can be manufactured commercially.

The transition raises operational concerns for county health systems, particularly the continuity of electronic records, integration with national platforms and the costs of replacing existing technology.

Lixudebart targets Claudin-1, a protein associated with tissue fibrosis, the process through which excessive scar tissue accumulates and damages organs.

The project will replace existing buildings with new facilities designed to support clinical development, commercial production and advanced manufacturing technologies.

Located in Kendall Square, a major biotechnology and life sciences hub, the new centre will operate alongside AstraZeneca’s genomic medicine facility at 100 Binney Street.

Under the agreement, Roche’s Genentech subsidiary will oversee development, regulatory activities, manufacturing and commercialisation across all indications.

IntraBio will become a wholly owned subsidiary of Shionogi Inc., the Japanese group’s US-based subsidiary in New Jersey.

The Bristol site’s focus on GMP small molecules adds to this portfolio, extending the company’s capacity to supply materials used in the development and production of advanced therapies.

The agreement was signed at the Precision Health Partnerships in Singapore event and witnessed by Ong Ye Kung, Singapore’s Minister for Health and Coordinating Minister for Social Policies.